DCOY

Decoy Therapeutics Inc.

NasdaqCMUSDEQUITY DELAYED

3.26

▼ 0.02 (0.61%)

MARKET · —

Price

Open

3.28

Prev close

3.28

Day high

3.43

Day low

3.17

Volume

15.15K

Market cap

—

P/E (TTM)

—

52W range

3.17 – 75.36

Trailing performance

Price return · vs SPY

Returnvs SPY

-10.61% -9.2%

-35.22% -39.0%

-50.23% -53.3%

-64.06% -75.1%

YTD

-58.91% -71.2%

-95.10% -115.1%

-99.70% -173.9%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

3.55

-8.14% from price

SMA 20

3.81

-16.03% from price

SMA 50

5.21

-38.56% from price

SMA 100

5.66

-42.38% from price

SMA 200

7.96

-59.81% from price

EMA 12

3.63

-10.27% from price

EMA 26

4.17

-21.83% from price

EMA 50

4.86

-32.93% from price

RSI (14)

31.5

Neutral

MACD (12,26,9)

-0.54

Hist 0.01

ATR (14)

0.36

11.27% of price

Realised vol 30D

103.9%

Annualised

Bollinger upper

4.46

20, 2σ

Bollinger lower

3.16

20, 2σ

50 / 200 cross

Death

5.21 vs 7.96

Trend bias

Below 200

-59.81%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.22

More volatile than market

Correlation to SPY

0.18

Largely independent

Realised vol 30D

103.9%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-95.5%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.36

11.27% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.26

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

DCOY · links out to the publisher

Decoy Therapeutics: Q2 Earnings Snapshot Associated Press · 10d ago Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform PR Newswire · 19d ago Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats PR Newswire · 26d ago Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors PR Newswire · 38d ago Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale MT Newswires · 43d ago Top Premarket Decliners MT Newswires · 53d ago Top Midday Gainers MT Newswires · 54d ago DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally? Stocktwits · 54d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.